Agios Pharmaceuticals, Inc.
AGIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001439222
In the last 90 days, Agios Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 238 institutions reported holding it in 13F filings for Q2 2026, worth $2.45B in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Agios Pharmaceuticals, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 206
- +21 vs. Q1 2024
- Shares held
- 58.1M
- −3.74M (−6.0%) vs. Q1 2024
- Total value
- $2.51B
- +$698.2M (+38.6%) vs. Q1 2024
- New holders
- 48
- 51 more added
- Sold out
- 27
- 82 more reduced
2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AGIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 238 | $2.45B |
| Q1 2026 | 234 | $2.12B |
| Q4 2025 | 238 | $1.67B |
| Q3 2025 | 221 | $2.55B |
| Q2 2025 | 216 | $2.05B |
| Q1 2025 | 221 | $1.76B |
| Q4 2024 | 225 | $1.97B |
| Q3 2024 | 208 | $2.58B |
| Q2 2024 | 206 | $2.51B |
| Q1 2024 | 187 | $1.81B |
| Q4 2023 | 170 | $1.33B |
| Q3 2023 | 146 | $1.46B |
| Q2 2023 | 153 | $1.68B |
| Q1 2023 | 165 | $1.36B |
| Q4 2022 | 160 | $1.67B |
| Q3 2022 | 168 | $1.64B |
| Q2 2022 | 157 | $1.31B |
| Q1 2022 | 161 | $1.74B |
| Q4 2021 | 161 | $1.95B |
| Q3 2021 | 165 | $2.81B |
| Q2 2021 | 186 | $3.63B |
| Q1 2021 | 175 | $3.37B |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Agios Pharmaceuticals, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,254,900 | $97.3M | 1.29% | −25,000−1.1% | Reduced |
| Price T Rowe Associates Inc | 2,777,259 | $119.8M | 0.01% | +764,266+38.0% | Added |
| Bellevue Group AG | 3,879,548 | $167.3M | 2.72% | −126,452−3.2% | Reduced |
| BlackRock Inc. | 4,859,002 | $209.5M | 0.00% | +200,907+4.3% | Added |
| Vanguard Group Inc | 5,496,737 | $237.0M | 0.00% | −75,284−1.4% | Reduced |
| Farallon Capital Management, L.L.C. | 5,654,502 | $243.8M | 1.44% | +63,900+1.1% | Added |
| T. Rowe Price Investment Management, Inc. | 0 | $0 | 0.00% | −928,596−100.0% | Sold out |
| Paradigm Biocapital Advisors LP | 0 | $0 | 0.00% | −400,000−100.0% | Sold out |
| Vestal Point Capital, LP | 0 | $0 | 0.00% | −325,000−100.0% | Sold out |
| Cutter Capital Management, LP | 0 | $0 | 0.00% | −288,580−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −122,282−100.0% | Sold out |
| Altitude Crest Partners Inc. | 0 | $0 | 0.00% | −113,100−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −101,612−100.0% | Sold out |
| Exome Asset Management LLC | 0 | $0 | 0.00% | −59,902−100.0% | Sold out |
| Parallax Volatility Advisers, L.P. | 0 | $0 | 0.00% | −48,434−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −35,734−100.0% | Sold out |
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −34,855−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −30,853−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −27,375−100.0% | Sold out |
| Prosight Management, LP | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Schroder Investment Management Group | 0 | $0 | 0.00% | −24,000−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −20,900−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −17,658−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −15,056−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −14,714−100.0% | Sold out |
| Entropy Technologies, LP | 0 | $0 | 0.00% | −9,787−100.0% | Sold out |
| Royce & Associates LP | 0 | $0 | 0.00% | −7,338−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −2,956−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −2,924−100.0% | Sold out |
| North Star Investment Management Corp. | 0 | $0 | 0.00% | −125−100.0% | Sold out |
| SYSTM Wealth Solutions LLC | 0 | $0 | 0.00% | −35−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Principal Securities, Inc. | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Credit Suisse AG | – | – | – | – | Not filed |
| Cutler Group LP | – | – | – | – | Not filed |